Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?
about
Chemotherapy-induced nausea and vomiting: incidence and characteristics of persistent symptoms and future directions NCCTG N08C3 (Alliance).Addressing the value of novel therapies in chemotherapy-induced nausea and vomiting.Pharmacogenetics of chemotherapy-induced nausea and vomiting.Personalizing supportive care in oncology patients using pharmacogenetic-driven treatment pathways.Irinotecan-induced toxicity pharmacogenetics: an umbrella review of systematic reviews and meta-analyses.A review of the literature on the relationships between genetic polymorphisms and chemotherapy-induced nausea and vomiting.Value of Supportive Care Pharmacogenomics in Oncology Practice.Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists.
P2860
Q37174198-F8A016A4-A5FC-4BA3-BE39-AC5FBE20C5AEQ38250191-820EFCA6-0DFA-411C-A628-C065A982089EQ38330216-6D8905D3-3095-4D21-A3C9-4EEC62229FA9Q38731079-3A8C95AB-52BF-480C-AE3A-9C5D1CDD2863Q38922471-6B65E612-65A7-4F38-9F47-DC6A6AAD6086Q49570044-7CD3CB60-C56D-4A37-A18D-7FF9652C465AQ52603826-DBB7D90D-E778-4DCA-9804-57738A682995Q55666180-8202F872-0EEC-490F-81CA-3187DB95EDB3
P2860
Does pharmacogenomics account for variability in control of acute chemotherapy-induced nausea and vomiting with 5-hydroxytryptamine type 3 receptor antagonists?
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Does pharmacogenomics account ...... e type 3 receptor antagonists?
@ast
Does pharmacogenomics account ...... e type 3 receptor antagonists?
@en
type
label
Does pharmacogenomics account ...... e type 3 receptor antagonists?
@ast
Does pharmacogenomics account ...... e type 3 receptor antagonists?
@en
prefLabel
Does pharmacogenomics account ...... e type 3 receptor antagonists?
@ast
Does pharmacogenomics account ...... e type 3 receptor antagonists?
@en
P2093
P2860
P1476
Does pharmacogenomics account ...... e type 3 receptor antagonists?
@en
P2093
Howard McLeod
Mary Roederer
Morgan Trammel
P2860
P2888
P304
P356
10.1007/S11912-013-0312-X
P577
2013-06-01T00:00:00Z